Legal & General Group
MLYS icon

Legal & General Group’s Mineralys Therapeutics MLYS Stock Holding History

Legal & General Group’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.04M Sell
38,473
-5,465
-12% -$160K ﹤0.01% 2132
2025
Q4 		$1.59M Sell
43,938
-1,491
-3% -$59.8K ﹤0.01% 2067
2025
Q3 		$1.72M Buy
45,429
+9,380
+26% +$203K ﹤0.01% 2041
2025
Q2 		$488K Buy
36,049
+33,467
+1,296% +$485K ﹤0.01% 2450
2025
Q1 		$41K Hold
2,582
– – ﹤0.01% 2753
2024
Q4 		$31.8K Hold
2,582
– – ﹤0.01% 2869
2024
Q3 		$31.2K Hold
2,582
– – ﹤0.01% 2884
2024
Q2 		$30.2K Buy
2,582
+900
+54% +$11.3K ﹤0.01% 2878
2024
Q1 		$21.7K Hold
1,682
– – ﹤0.01% 2928
2023
Q4 		$14.5K Buy
1,682
+489
+41% +$3.84K ﹤0.01% 3156
2023
Q3 		$11.4K Sell
1,193
-251
-17% -$3.27K ﹤0.01% 3243
2023
Q2 		$24.7K Buy
1,444
+171
+13% +$2.56K ﹤0.01% 3023
2023
Q1 		$19.9K Buy
+1,273
New +$21.4K ﹤0.01% 3069

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Legal & General Group's MLYS Position: Q1 2026 in Review

Legal & General Group reduced its Mineralys Therapeutics (MLYS) stake by 12% in Q1 2026, selling an estimated $160K and leaving 38,473 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #2132.

Legal & General Group first reported a position in MLYS in Q1 2023 and has held it in 13 quarters since. The position peaked at $1.72M in Q3 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Legal & General Group held 38,473 shares of Mineralys Therapeutics worth $1.04M as of Q1 2026.
  • Legal & General Group sold 5,465 Mineralys Therapeutics shares in Q1 2026, an estimated $160K.
  • Mineralys Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2132 holding.
  • Legal & General Group first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Legal & General Group's Mineralys Therapeutics position peaked at $1.72M in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.